3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Breast Neoplasms
7244
Neoplasms
4539
Prostatic Neoplasms
3489
Colorectal Neoplasms
2940
Carcinoma, Non-Small-Cell Lung
2831
Lung Neoplasms
2547
Leukemia, Myeloid, Acute
1982
Pancreatic Neoplasms
1874
Multiple Myeloma
1811
Carcinoma, Hepatocellular
1733
Neoplasm Metastasis
1585
Stomach Neoplasms
1502
Lymphoma
1457
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1435
Head and Neck Neoplasms
1435
Brain Neoplasms
1373
Melanoma
1348
Ovarian Neoplasms
1342
Leukemia
1303
Rectal Neoplasms
1270
Recurrence
1255
Colonic Neoplasms
1204
Glioblastoma
1138
Uterine Cervical Neoplasms
1096
Lymphoma, Non-Hodgkin
1066
Leukemia, Lymphocytic, Chronic, B-Cell
989
Esophageal Neoplasms
965
Lymphoma, Follicular
936
Lymphoma, Large B-Cell, Diffuse
932
Squamous Cell Carcinoma of Head and Neck
921
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Interventional
×
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled